Skip to content

Study · Case report or series · n = 6 · 2010

1 result

Concordant and discordant adrenocorticotropin (ACTH) responses induced by growth hormone-releasing peptide-2 (GHRP-2), corticotropin-releasing hormone (CRH) and insulin-induced hypoglycemia in patients with hypothalamopituitary disorders: evidence for direct ACTH releasing activity of GHRP-2.

Kimura T, Shimatsu A, Arimura H, Mori H, Tokitou A, Fukudome M, Nakazaki M, Tei C

Endocrine journal17 Apr 2010Cited by 8 (Europe PMC)

PMID20431231 (opens in a new tab)DOI10.1507/endocrj.k10e-017 (opens in a new tab)PepBankPUB-20431231
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In 6 patients with hypothalamo-pituitary disorders, significant ACTH release was observed during the GHRP‑2 test, while ITT produced no significant ACTH or cortisol response.

    In plain wordsIn 6 patients with pituitary-area disease, GHRP‑2 caused a clear ACTH rise, while the insulin test did not.

    Peptide
    GHRP-2
    Outcome
    IncreaseACTH release during GHRP-2 test
    Study

    n = 6

    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    None of the 6 patients showed any significant ACTH or cortisol responses to ITT, but significant ACTH release was observed during CRH and GHRP-2 tests.
    1 context sentence
    Summary · context
    To evaluate the role of GHRP-2 in assessing the HPA axis, we examined 6 patients with various hypothalamo-pituitary disorders, and measured ACTH and cortisol responses during provocative tests (ITT, CRH, and GHRP-2 test).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.